1163729-47-2

Usage

Uses

Used in Pharmaceutical Industry:
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid serves as a crucial building block in the synthesis of a variety of drugs and pharmaceutical intermediates, leveraging its structural and chiral properties to enhance drug development processes.
Used in Medicinal Chemistry:
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid is utilized in medicinal chemistry for its potential to contribute to the design and synthesis of new pharmaceuticals, particularly those that require specific stereochemical configurations for optimal biological activity.
Used in Drug Discovery:
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid is employed in drug discovery efforts, where its unique structural features can be exploited to identify and develop novel therapeutic agents with improved pharmacological profiles.
Used in Chemical Research:
4-hydroxy-4-(trifluoromethyl)cyclohexanecarboxylic acid also finds application in chemical research, where its properties are studied to understand its reactivity, stability, and potential interactions with other molecules, furthering the knowledge base for future chemical and pharmaceutical applications.

Upstream product

• 62596-26-3 benzyl 4-oxocyclohexane-1-carboxylate 
• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

PRIMARY CARBOXAMIDES AS BTK INHIBITORS

The invention provides carboxamide compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions, including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing spondylitis, interstitial cystitis, asthma, systemic lupus erythematosus, lupus nephritis, B cell chronic lymphocytic lymphoma, multiple sclerosis, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, B-cell non-Hodgkin's lymphoma, activated B-celllike diffuse large B-cell, lymphoma, multiple myeloma, diffuse large B-celllymphoma, follicular lymphoma, hairy cell leukemia or Lymphoblastic lymphoma.